October 20, 2009 -- Teijin Pharma announced today the signing of an exclusive sublicense agreement for TMX-67 (febuxostat) between Ipsen of France, the European TMX-67 licensee, and the Menarini Group of Italy. Discovered and developed by Teijin Pharma, TMX-67 is a novel drug for the treatment of hyperuricemia in patients with gout, and is a strategic product for the expansion of the company's overseas businesses.
The details can be read here.
No comments:
Post a Comment